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Abstract. Cancer/testis antigens (CTAs) are a large family 
of tumor-associated antigens expressed in human tumors of 
different histological origin, but not in normal tissues, with 
the exception of the testes and placenta. Numerous immu-
nohistochemical studies have reported associations between 
CTA expression and a negative estrogen receptor (ER) 
status in breast tumors, and demonstrated that CTAs are 
frequently expressed in tumors with higher nuclear grade. 
The expression of CTAs has not been studied as extensively 
in ductal carcinoma in situ (DCIS) as it has been in inva-
sive breast cancer. The present retrospective study included 
archived paraffin-embedded specimens from 83 patients 
diagnosed with DCIS in the period between January 2007 
and December 2014. The follow-up time for local recurrence 
ranged between 1 and 8 years (mean, 5.02 years). Antigens 
from the melanoma-associated antigen gene (MAGE) family, 
namely multi-MAGE-A, MAGE-A1, MAGE-A10 and New 
York esophageal squamous cell carcinoma 1 (NY-ESO-1) 
antigen, were evaluated by immunostaining and their subcel-
lular location was investigated. Presence of tumor‑infiltrating 
lymphocytes (TILs) was evaluated on all sections, together 
with the histopathological variables of DCIS. Specific 
tested antigens exhibited associations with histopathological 
parameters for DCIS and all demonstrated statistically 
significant associations with nuclear staining, simultaneous 
cytoplasmic and nuclear staining, and local recurrence. 
Antigen MAGE‑A10 demonstrated a significant association 
with higher expression of ER (P=0.005) and higher tumor 
nuclear grade (P=0.001), cytoplasmic staining (P=0.029) 
and antigen NY-ESO-1 with higher tumor size (P=0.001), 
expression of TILs (P=0.001) and R1 resection (P=0.001). 
A χ2 test revealed significant associations between simulta-
neous cytoplasmic and nuclear staining and local recurrence 
(P=0.005), central necrosis (P=0.016), and the expression 
of ER (P=0.003) and progesterone receptor (PR) (P=0.010). 
Additional analysis revealed an association between antigen 
MAGE-A10 and TILs (P=0.05). Additional analysis of 
TILs indicated that they were significantly associated with 
tumor grade (P=0.023), central necrosis (P<0.001), ER 
(P=0.003) and PR (P=0.029). Overall, CTAs from the MAGE 
family (MAGE-A1, multi-MAGE-A and MAGE-A10) and 
NY-ESO-1 associate with histopathological predictive vari-
ables of DCIS. The expression of antigens NY-ESO-1 and 
MAGE-A10 could serve an important role in the treatment of 
patients with negative histopathological predictive variables, 
but further analysis is required. Simultaneous cytoplasmic 
and nuclear protein expression of MAGE-A family and 
NY-ESO-1 CTAs may represent an independent marker for 
local recurrence. Taken together, the present data suggest that 
CTAs are not perfect indicators of invasiveness for DCIS, 
but could inform treatment strategies for patients when 
taken in combination with other histopathological predictive 
variables. However, this was a small study and further larger 
studies will be necessary to confirm the current findings.
Introduction
Ductal carcinoma in situ (DCIS) is a non-invasive type of 
breast cancer that evolves in the milk ducts of the breast and 
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remains located there. DCIS is a non-obligate precursor of 
invasive breast cancer and up to 40% of these lesions progress 
to invasive disease if untreated (1). The incidence of DCIS 
is rising, most likely due to increased use of mammographic 
screening and the transition from screen‑film mammography 
to digital mammography (2). DCIS is not one entity but a 
heterogeneous group of at least four subtypes (luminal A, 
luminal B, Her 2 overexpressed and triple negative-very 
rare) (3). It remains unclear which type of DCIS is more likely 
to progress to invasive breast cancer and therefore will require 
more intensive treatment.
Cancer/testis antigens (CTAs) are a large family of 
tumor-associated antigens expressed in human tumors of 
different histological origin, but not in normal tissues, with 
the exception of the testis and placenta (4). This unique class 
of tumor-associated antigens was discovered in the early 
1990s and the first to be identified was melanoma‑associated 
antigen-1 (MAGE-1) in melanoma patients (5,6). CTAs may 
be divided into two large groups, depending on whether 
they are encoded on the X chromosome (X-CTA genes) 
or not (non-X-CTA genes) (7). X-CTA genes include the 
synovial sarcoma X (SSX) family, the GAGE/PAGE/XAGE 
super-families and the MAGE-A, MAGE-C and New York 
esophageal squamous cell carcinoma 1 (NY-ESO-1) multi-
gene families, among others (7,8). Antigens in this group are 
widely and variably expressed among tumors of different 
histotypes (4). Expression of CTAs is highly variable and 
may be observed frequently in melanomas and bladder, lung, 
ovarian and hepatocellular carcinomas, but rarely in renal, 
colon and gastric cancer or hematological malignancies (9). 
In breast cancer, multiple immunohistochemical studies 
have reported an association between CTA expression and 
negative estrogen receptor (ER) status in breast tumors, 
and have demonstrated that CTAs are frequently expressed 
in tumors with higher nuclear grade (10,11). Spontaneous 
humoral and cell-mediated immune responses against 
several CTAs, including MAGE-A1 (6) and NY-ESO-1 
antigens (12) has led to the proposal that CTAs could 
represent attractive cancer immunotherapy targets and has 
inspired research into the development of antigen‑specific 
vaccines (9).
The expression of CTAs in DCIS has not been studied 
as extensively as in invasive breast cancer. However, in two 
studies, the expression of CTAs in DCIS was studied and 
it was demonstrated that NY-ESO1 is expressed in a high 
proportion of DCIS tissues, particularly those that are 
ER-negative (10,11).
The present study investigated the expression of CTAs 
from the MAGE family (multi MAGE-A, MAGE-A1 and 
MAGE-A10) and NY-ESO-1 in DCIS, and their association 
with standard histopathological parameters for DCIS [tumor 
size, tumor grade, expression of ER and progesterone receptor 
(PR), necrosis and margin] and local recurrence. The evaluation 
of tumor‑infiltrating lymphocytes (TILs) was also performed.
Materials and methods
Patients and samples. This retrospective study included 
archived paraffin-embedded specimens from 83 patients 
diagnosed with DCIS who underwent segmentectomy 
surgery at the University Hospital for Tumors, Sisters 
of Mercy University Hospital Center (Zagreb, Croatia) 
between January 2007 and December 2014. The patients 
were all female, aged between 40 and 70 years old (mean 
age 57.4 years). All cases of surgically resected DCIS were 
reviewed in the current study, and histopathological param-
eters (tumor size, histological tumor grade, ER and PR status, 
necrosis and margin) were routinely assessed and recorded 
in a database. All patients received radiotherapy following 
breast-conserving surgery (lumpectomy) and certain patients 
(those who were receptor-positive) received hormone therapy 
for 5 years. Follow-up ranged between 1 and 8 years (mean, 
5.02 years). This study received ethical approval from 
the Sisters of Mercy University Hospital Center. Written 
informed patient consent was received at the time of the 
material collection.
Histology and immunohistochemistry. Tumors were fixed in 
10% buffered formalin for approximately 24 h at 4˚C, cut at 
3-4 milimeters and sampled in 3-7 sections. The specimens 
were embedded in paraffin, routinely cut and stained with 
hematoxylin and eosin (H&E). In each case, the available H&E 
sections were reviewed and slides with the deepest portion of 
tumor penetration were selected for immunohistochemical 
analysis.
A total of 4 new 5-µm sections were cut from the 
paraffin‑embedded blocks of each sample for analysis. Tissue 
slides from paraffin‑embedded breast cancer tumor samples 
were placed on Silane (3-aminopropyltriethoxysilane, A 
3,648, Sigma-Aldruch, Merck KgaA, Darmstadt, Germany). 
Following deparaffinization, slides were heated in an 800‑W 
microwave oven at maximum power for 8.5 min, held in 
10 mmol/l citrate buffer (pH 6.0) for 5 min and then rinsed 
with a phosphate buffer solution (PBC, pH 7.2).
Four monoclonal antibodies were used to determine the 
expression of analyzed proteins in DCIS (antibodies are gift 
from Dr. Spagnoli, Basel, Switzerland, they are not commercial 
antibodies). Monoclonal antibodies (mAbs) recognizing the 
following CTAs were used: Anti-MAGE-A1 (clone 77B), Anti 
multi-MAGE-A (clone 57B), anti-MAGE-A10 (clone 3GA11) 
and anti-NY-ESO-1 (clone D8.38). These mouse monoclonal 
antibodies CTAs (77B, 57B, 3GA11 and D8.38) mAb were 
used undiluted (undiluted supernatants). 57B was generated 
on immunization of mice with recombinant MAGE-A3 (13). 
However, this antibody recognizes a variety of MAGE-A mole-
cules, and it is considered a multi‑MAGE‑A‑specific reagent. 
D8.38 antibody, recognizing NY-ESO-1 and its homologous 
LAGE-1 CTA, has been previously described (14). 3GA11 
antibody recognizing MAGE-A10 (15) and 77B recognizing 
MAGE-A1 has also been previously described (16).
TMA staining was performed as described previously (17). 
Briefly, tissue slides from paraffin‑ embedded breast cancer 
tumor samples were placed on Silane (3-aminopropyltriethoxysi-
lane, A 3648, Sigma, St. Louis MO, USA) and incubated for 
20 min in a thermostat at 60°C. The sections were then deparaf-
finized and incubated for 3x5 min in 10 mmol/l of citrate buffer 
(pH 6.0) in a microwave oven at 800 W. Subsequently, tissue 
slides were washed with phosphate buffered saline (PBS) buffer 
(pH 7.2), and endogenous peroxidase activity was blocked 
by a 5-min treatment with hydrogen peroxide (No. S2023, 
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Table I. Frequency and percentage of study samples with given 
histopathological variables. 
Parameters n (%) P-value
Tumor size, mm  0.078
  <1.2 50 (60)
  >1.2 33 (40)
Tumor grade  <0.001a
  1 18 (22)
  2, 3 65 (78)
Central necrosis  0.124
  No 34 (41)
  Yes 49 (59)
TIL  0.510
  No 45 (54)
  Yes 38 (46)
Multi-MAGE-A  <0.001a
  No 13 (16)
  Yes 70 (84)
MAGE-A10  1.000
  No 42 (51)
  Yes 41 (49)
MAGE-A1  <0.001a
  No 6 (7)
  Yes 77 (93)
NY-ESO-1  <0.001a
  No 22 (27)
  Yes 61 (73)
ER  <0.001a
  No 24 (29)
  Yes 59 (71)
PR  0.028a
  No 31 (37)
  Yes 52 (63)
R1  0.661
  No 39 (47)
  Yes 44 (53)
Cytoplasmic staining  0.004a
  No 28 (34)
  Yes 55 (66)
Nuclear staining  <0.001a
  No 75 (90)
  Yes 8 (10)
Cytoplasmic and nuclear staining  <0.001a
  No 68 (82)
  Yes 15 (18)
Total staining  <0.001a
  No 59 (71)
  Yes 24 (29)
Local recurrence  <0.001a
  No 76 (92)
  Yes 7 (8)
aStatistically significant result. TIL, tumor‑infiltrating lymphocyte; 
MAGE, melanoma-associated antigen; NY-ESO-1, New York esoph-
ageal squamous cell carcinoma 1 antigen; ER, estrogen receptor; 
PR, progesterone receptor; R1, positive surgical margin.
Table II. Sensitivity, specificity and cutoff values for antigen 
and receptor detection.
 Sensitivity, Specificity, Cutoff value,
Parameters (%) (%)  (%)
ER 100 100 >20
PR 100 100 >30
Multi-MAGE-A 100 100 >0
MAGE-A10 100 100 >0
MAGE-A1 100 100 >0
NY-ESO-1 98 91 >0 
MAGE, melanoma-associated antigen; NY-ESO-1, New York esopha-
geal squamous cell carcinoma 1 antigen; ER, estrogen receptor; PR, 
progesterone receptor.
Figure 1. Immunohistochemistry staining of DCIS samples using mAb 
specific to NY‑ESO‑1 (clone D8.38) (observed in brown) and MAGE‑A1 
(mAb clone 77B). Sections presented variable (A) nuclear NY-ESO-1 
staining, and (B) cytoplasmic and (C) nuclear MAGE-A1 staining. Original 
magnification, x10. DCIS, ductal carcinoma in situ; NY-ESO-1, New York 
esophageal squamous cell carcinoma 1 antigen; MAGE-A1, melanoma-asso-
ciated antigen A1; mAb, monoclonal antibody.
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Dako, Carpinteria, CA, USA). Slides were then washed with 
PBS-buffer and incubated for 90 min with multi-MAGE-A 
57B, MAGE-A1 77B, MAGE-A10 3GA11 or NY-ESO-1 D8.38 
undiluted supernatants at room temperature. After washing in 
PBS, bound primary antibodies were detected using biotinyl-
ated anti-mouse secondary antibody (EnVision FLEX, High pH 
Kit, catalogue number 8010; Dako, ready for use) for 45 min and 
visualized with diaminobenzidine as chromogen on Autostainer 
Link 48 (Dako). Slides were counterstained with hematoxilyn, 
dehydrated, cleared and cover-slipped.
Melanomas and testicular tissues expressing CTAs from 
University Hospital for Tumors, Sisters of Mercy University 
Hospital Center (Zagreb, Croatia) were used as positive controls 
throughout the study, and healthy skin tissue and unstained tumor 
cells served as the negative control. The specimens were described 
as positive or negative for TIL according to their presence in the 
samples. The positive cells were scored in whole tumor at x200 
magnification using a light microscope on selected slides. All 
samples were examined independently by three observers and 
any difference was resolved by a joint review.
Table III. Mann-Whitney U test results of the expression of cancer/testis antigens and histopathological variables.
Parameters Multi-MAGE-A MAGE-A10 MAGE-A1 NY-ESO-1
Tumor size    
  U 1,909 3,112 1,618 2,282
  P-value 0.001a 0.216 0.001a 0.001a
Tumor grade    
  U 3,237 2,448 2,946 3,278
  P-value  0.327 0.001a 0.010a 0.474
Central necrosis    
  U 2,573 3,112 2,282 2,946
  P-value  0.001a 0.217 0.001a 0.051
TILs    
  U 2,116 3,320 1,826 2,490
  P-value  0.001a 0.644 0.001a 0.001a
ER    
  U 2,988 2,697 2,697 3,361
  P-value  0.043a 0.005a 0.001a 0.732
PR    
  U 2,697 2,988 2,407 3,071
  P-value  0.002a 0.088 0.001a 0.138
R1    
  U 2,365 3,320 2,075 2,739
  P-value  0.001a 0.644 0.001a 0.001a
Cytoplasmic staining    
  U 2,822 2,863 2,531 3,195
  P-value  0.008a 0.029a 0.001a 0.315
Nuclear staining    
  U 871 2,075 581 1,245
  P-value  0.001a 0.001a 0.001a 0.001a
Cytoplasmic and nuclear staining    
  U 1,162 2,365 871 1,535
  P-value  0.001a 0.001a 0.001a 0.001a
Total staining    
  U 1,535 2,739 1,245 1,909
  P-value  0.001a 0.007a 0.001a 0.001a
Local recurrence    
  U 830 2,033 539 1,203
  P-value  0.001a 0.001a 0.001a 0.001a 
aStatistically significant result. U, Mann‑Whitney U value; MAGE, melanoma‑associated antigen; NY‑ESO‑1, New York esophageal squamous 
cell carcinoma 1 antigen; TIL, tumor‑infiltrating lymphocyte; ER, estrogen receptor; PR, progesterone receptor; R1, positive surgical margin.
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Table IV. Multivariate logistic regression for cancer/testis antigens and histopathological parameters.
Parameters Multi-MAGE-A MAGE-A10 MAGE-A1 NY-ESO-1
Cytoplasmic staining    
  P-value 0.363 0.427 0.006a 0.181
  OR 0.363 0.651 74.761 0.990
  95% CI 0.041-3.223 0.226-1.877 3.344-1674.250 0.976-1.005
Nuclear staining    
  P-value 0.996 0.873 0.997 0.425
  OR 25.2x106 1.135 2.97x106 1.01
  95% CI  0.000-0.000 0.234-5.370 0.000-0.000 0.986-1.034
Cytoplasmic and nuclear staining
  P-value 0.994 0.503 0.996 0.386
  OR 28.3x10-6 1.522 3.51x106 1.007
  95% CI  0.000-0.000 0.445-5.206 0.000-0.000 0.991-1.075
Total staining    
  P-value 0.936 0.163 0.043a 0.111
  OR 1.080 2.240 0.070 1.014
  95% CI  0.180-6.450 0.720-65.930 0.005-0.91 0.628-6.79
Tumor size    
  P-value 0.174 0.619 0.685 0.915
  OR 3.258 0.788 0.617 1.065
  95% CI  0.592-17.926 0.308-2.013 0.059-6.370 0.333-3.400
Tumor grade    
  P-value 0.478 0.348 0.310 0.108
  OR 1.830 1.733 4.298 0.169
  95% CI 0.344-9.735 0.549-5.465 0.257-71.641 0.019-1.472
Central necrosis    
  P-value 0.318 0.196 0.487 0.331
  OR 2.096 1.877 2.185 0.542
  95% CI  0.490-8.962 0.721-4.883 0.240-19.834 0.158-1.861
TILs    
  P-value 0.089 0.106 0.067 0.328
  OR 6.572 2.203 0.075 1.850
  95% CI  0.750-57.578 0.845-5.740 0.004-1.195 0.539-6.346
ER    
  P-value 0.253 0.066 0.991 0.741
  OR 2.472 0.356 0.987 1.233
  95% CI  0.524-11.658 0.118-1.070 0.100-9.663 0.355-4.273
PR    
  P-value 0.149 0.088 0.851 0.929
  OR 2.992 0.416 1.229 1.055
  95% CI  0.675-13.263 0.152-1.138 0.141-10.687 0.323-3.448
R1    
  P-value 0.575 0.604 0.894 0.344
  OR 1.508 1.276 1.154 0.572
  95% CI  0.357-6.361 0.507-3.214 0.139-9.591 0.180-1.817
Local recurrence    
  P-value 0.997 0.71 0.999 0.996
  OR 38.4x106 0.757 0.000 1.298
  95% CI  0.000-0.000 0.146-3.705 - 8.35x10-49-2.02x1048
aStatistically significant result. MAGE, melanoma‑associated antigen; NY‑ESO‑1, New York esophageal squamous cell carcinoma 1 antigen; 
OR, odds ratio; TIL, tumor‑infiltrating lymphocyte; ER, estrogen receptor; PR, progesterone receptor; R1, positive surgical margin.
ROGULJIC et al:  POSSIBLE PREDICTIVE ROLE OF CANCER/TESTIS ANTIGENS IN BREAST DCIS7250
Scoring. Multi-MAGE-A, MAGE-A1, MAGE-A10 and 
NY-ESO-1 staining results were scored using the Allred 
scoring system (18). This method takes into account percent-
ages of positive cells (scored on a 0-3 scale) and the intensity 
of their staining (scored on a 0-3 scale). If the expression of 
CTAs was detectable in <10% of tumor cells it was scored 
as 1, in 10-50% of tumor cells it was scored as 2, or in >50% 
of tumor cells it was scored as 3. Score 0 was attributed to 
negative samples. The percentage of positive cells was then 
multiplied by the intensity of staining,  0, no reaction; 1, weak 
reaction; 2, moderate reaction; 3, strong reaction and the final 
score ranged between 0 (no staining) and 9 (diffuse and strong 
staining). The final results were further classified as 0 (no 
staining), 1 (score 1, 2 or 3), 2 (score 4, 5 or 6) and 3 (score 7, 8 
or 9). Staining was considered positive (score 2 or 3) where all 
or a majority of the tumor cells were stained.
Statistical analysis. Data were analyzed using Microsoft Excel 
2010 (Microsoft Corporation, Redmond, WA, USA), MedCalc 
(version 18.2.1; MedCalc Software bvba, Ostend, Belgium) and 
IBM SPSS Statistics (version 21.0; IBM Corp., Armonk, NY, 
USA). Descriptive statistics were calculated for the expression of 
proteins from the MAGE family (multi-MAGE-A, MAGE-A1 
and MAGE-A10), NY-ESO-1, standard histopathological 
parameters for DCIS (tumor size, tumor grade, expression of ER 
and PR, necrosis, margin and TILs) and local recurrence. Cutoffs 
were established by receiver-operating characteristic curve 
analysis. Associations between variables were analyzed with the 
Mann Whitney U signed rank test and with Fisher's exact test. 
The χ2 test was used for the analysis of associations between 
histopathological variables, staining and TILs. Furthermore, a 
multivariate logistic regression model was used to predict the 
effect of a series of variables (antigens) on a binary response 
variable (histopathological parameters for DCIS). P<0.05 was 
considered to indicate a statistically significant difference.
Results
Patient population. This retrospective study included a total 
of 83 patients who were diagnosed with DCIS and underwent 
surgery between January 2007 and December 2014. Data on 
tumor size, tumor grade, expression of ER and PR, necrosis, 
margin, TILs, and expression of CTAs multi-MAGE-A, 
MAGE-A1, MAGE-A10 and NY-ESO-1 in samples are 
summarized in Table I. Antigens MAGE-A1, multi-MAGE-A, 
NY-ESO-1 and MAGE-A10 were expressed in 93, 84, 73 and 
49% of cases, respectively (Table I). The cutoff values for the 
detection of ER, PR and the CTAs were calculated (Table II). 
Since expression of CTAs has been previously detected in 
different intracellular locations (19), the present study focused 
on three different staining patterns, namely nuclear, cyto-
plasmic, and simultaneous cytoplasmic and nuclear expression 
of multi-MAGE-A, MAGE-A1, MAGE-A10 and NY-ESO-1 in 
breast DCIS cells (Fig. 1). This specifies what was focused on, 
but not what was found.
Associat ions bet ween mult i‑MAGE‑A, MAGE‑A1, 
MAGE‑A10 and NY‑ESO‑1 expression and histopatholog‑
ical parameters of DCIS. All the tested antigens exhibited 
associations with histopathological parameters for DCIS, and 
they all demonstrated statistically significant associations 
with nuclear staining, simultaneous cytoplasmic and nuclear 
staining, and local recurrence (Table III). Antigen MAGE-A10 
was significantly associated with higher expression of ER 
(P=0.005), higher tumor grade (P=0.001) and cytoplasmic 
staining (P=0.029), and antigen NY-ESO-1 with larger tumor 
size (P=0.001), expression of TILs (P=0.001) and R1 resec-
tion (P=0.001). The multivariate logistic regression model, 
antigen MAGE-A1 expression demonstrated a significant 
association with cytoplasmic staining (P=0.006, Table IV). 
The association between the subcellular expression pattern 
of CTA and histopathological parameters was analyzed. The 
χ2 test identified a significant association between the cyto-
plasmic staining pattern and the expression of ER (P=0.012) 
and PR (P=0.029). It also identified a significant associa-
tion between local recurrence and cytoplasmic and nuclear 
CTA expression pattern in breast DCIS cells (P=0.005). 
Simultaneous cytoplasmic and nuclear staining was also 
significantly associated with central necrosis (P=0.016), and 
the expression of ER (P=0.003) and PR (P=0.010) (Table V). 
The analysis of association between cytoplasmic staining, 
nuclear staining, cytoplasmic and nuclear staining, and total 
staining with histopathological variables showed similar 
results (Table VI).
Table V. Associations between histopathological variables and staining (χ2 test).
    Cytoplasmic Nuclear Nuclear and Total
Parameters ER PR R1 staining staining cytoplasmic staining staining
Tumor size 0.224 0.088 0.449 0.174 0.167 0.546 0.821
Tumor grade 0.014a 0.002a 0.175 0.968 0.254 0.119 0.479
Central necrosis 0.004a <0.001a 0.072 0.101 0.834 0.016a 0.163
TILs 0.003a 0.029a 0.413 0.138 0.621 0.073 0.623
ER - - - 0.012a 0.797 0.003a 0.007a
PR - - - 0.029a 0.447 0.010a 0.012a
R1 0.726 0.797 - 0.053 0.572 0.081 0.038a
Local recurrence 0.395 0.753 0.308 0.171 0.367 0.005a 0.085 
aStatistically significant result. ER, estrogen receptor; PR, progesterone receptor; R1, positive surgical margin; TIL, tumor‑infiltrating lymphocyte. 
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Additional analysis of the association between the expres-
sion of CTA and standard histopathological parameters with 
Fisher's exact test indicated that expression of MAGE-A10 
antigen was associated with TILs (P=0.05; Table VII). 
The additional analysis of TILs and histopathological vari-
ables indicated a significant association with tumor grade 
(P=0.023), central necrosis (P<0.001) and expression of 
ER (P=0.003) and PR (P=0.029) (Table VIII). Multivariate 
logistic regression models indicated an association between 
TILs and tumor size (P=0.038), tumor grade (P=0.030), 
central necrosis (P=0.001), and expression of ER (P=0.005) 
and PR (P=0.031) (Table IX).
Discussion
The role of CTAs has not been studied as extensively in DCIS 
as it has in invasive breast cancer. A small number of studies 
have analyzed the expression of CTAs in DCIS, but none have 
analyzed the associations between the expression of CTAs 
and histopathological predictive variables. In the current 
study, associations between histopathological predictive 
variables and the expression of CTAs from the MAGE family 
(multi-MAGE-A, MAGE-A1 and MAGE-A10) and NY-ESO-1 
were evaluated. Caballero et al (10) recently reported that 
antigen NY-ESO-1 is a predictor of good prognosis in patients 
with DCIS. In this study, NY-ESO-1 was predominantly 
expressed in ER-negative DCIS and patients who expressed 
NY-ESO-1 antigen did not suffer from recurrence over a 
10-year period. Therefore, it was concluded that NY-ESO-1 
has a ‘protective effect’ and is expressed in patients who will 
not subsequently develop invasive breast cancer.
In the present study, all examined antigens were demon-
strated to be associated with histopathological predictive 
variables of DCIS. Different staining patterns (cytoplasmic, 
nuclear, or cytoplasmic and nuclear) and nuclear protein expres-
sion of MAGE-A family and NY-ESO-1 CTAs were observed. 
All tested antigens were significantly associated with nuclear 
staining, simultaneous cytoplasmic and nuclear staining, 
and local recurrence. Using the multivariate logistic regres-
sion model, antigen MAGE-A1 expression demonstrated a 
significant association with cytoplasmic staining (P=0.006). A 
similar staining pattern for MAGE-A antigen has been reported 
previously in DCIS and in invasive breast cancer, as well as 
in other malignant tumors (9,12,20). Notably, simultaneous 
cytoplasmic and nuclear staining was significantly associated 
with local recurrence, central necrosis, and the expression of 
ER and PR. This was also previously observed in head and 
neck carcinoma, where simultaneous cytoplasmic and nuclear 
protein expression of MAGE-A family and NY-ESO-1 CTAs 
represented an independent marker for poor survival (19). 
In the present study, antigen MAGE-A10 was revealed to be 
significantly associated with higher expression of ER and 
higher tumor grade, and antigen NY-ESO-1 with higher tumor 
size, expression of TILs and R1 resection. Antigen NY-ESO-1 
was predominantly expressed in ER-negative DCIS, which 
is consistent with the results from a previous study (10). 
An association between the expression of MAGE-A10 and 
TILs was also observed (P=0.05). In the current analysis 
of TILs and their significance in DCIS, a significant asso-
ciation was identified between TILs and tumor grade, central 
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necrosis, and negative ER and PR status. These findings are 
consistent with previous studies (21-23).
In summary, associations between CTAs from the MAGE 
family (MAGE-A1, multi-MAGE-A and MAGE-A10) and 
NY-ESO-1, and histopathological predictive variables of DCIS, 
were revealed. An association was also observed between the 
MAGE-A10 antigen and the presence of TILs. These results 
indicate that MAGE-A10 and NY-ESO-1 may serve a function 
in DCIS and could present a potential target for a novel treat-
ment strategy. Additional analysis in a larger group of patients 
will be required to evaluate this further. Simultaneous cyto-
plasmic and nuclear protein expression of MAGE-A family 
and NY-ESO-1 CTAs may represent an independent marker 
for local recurrence. In conclusion, CTAs are not perfect 
indicators of invasiveness for DCIS, but in combination with 
other histopathological predictive variables, they could inform 
treatment strategies for patients. However, the present study 
was small and fresh-frozen tissue samples were not available, 
therefore the additional analysis on mRNA and protein level 
was not performed. Further larger studies are warranted to 
expand the cohort of patients under investigation and further 
support the present data at the gene expression level.
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